American Capital Management Inc. grew its holdings in shares of Inogen Inc (NASDAQ:INGN) by 104.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,310 shares of the medical technology company’s stock after buying an additional 11,930 shares during the quarter. American Capital Management Inc.’s holdings in Inogen were worth $2,223,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in INGN. Janus Henderson Group PLC boosted its stake in shares of Inogen by 15,943.5% during the 1st quarter. Janus Henderson Group PLC now owns 552,056 shares of the medical technology company’s stock valued at $52,650,000 after buying an additional 548,615 shares during the last quarter. William Blair Investment Management LLC lifted its stake in Inogen by 62.2% during the first quarter. William Blair Investment Management LLC now owns 1,048,413 shares of the medical technology company’s stock worth $99,987,000 after purchasing an additional 402,150 shares during the last quarter. Norges Bank bought a new position in Inogen during the fourth quarter worth $48,104,000. Thrivent Financial for Lutherans lifted its stake in Inogen by 210.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 178,152 shares of the medical technology company’s stock worth $22,121,000 after purchasing an additional 120,785 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Inogen by 90.2% during the fourth quarter. Jennison Associates LLC now owns 232,179 shares of the medical technology company’s stock worth $28,830,000 after purchasing an additional 110,098 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.
Shares of INGN opened at $66.09 on Wednesday. Inogen Inc has a 12-month low of $62.31 and a 12-month high of $287.79. The firm has a market cap of $1.45 billion, a P/E ratio of 28.73, a PEG ratio of 2.61 and a beta of 1.58. The company has a current ratio of 7.35, a quick ratio of 6.70 and a debt-to-equity ratio of 0.02.
Inogen (NASDAQ:INGN) last issued its earnings results on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). Inogen had a return on equity of 15.59% and a net margin of 12.56%. The company had revenue of $90.20 million during the quarter, compared to analyst estimates of $89.69 million. During the same period in the prior year, the business earned $0.48 earnings per share. Inogen’s quarterly revenue was up 14.1% on a year-over-year basis. As a group, analysts predict that Inogen Inc will post 1.63 EPS for the current fiscal year.
INGN has been the topic of several research analyst reports. Zacks Investment Research cut Inogen from a “buy” rating to a “hold” rating in a research note on Thursday, February 14th. Needham & Company LLC restated a “strong-buy” rating and set a $191.00 price objective (down from $280.00) on shares of Inogen in a research note on Wednesday, February 27th. ValuEngine cut Inogen from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, JPMorgan Chase & Co. cut Inogen from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $175.00 to $72.00 in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Inogen currently has a consensus rating of “Hold” and a consensus price target of $121.60.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Story: What is systematic risk?
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.